The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Nicolas Isambert
Consulting or Advisory Role - Amgen; Daichii; Eisai; Ipsen; Pfizer; Transgene
Travel, Accommodations, Expenses - AstraZeneca; Novartis; PharmaMar; Roche/Genentech
 
Jean-Philippe Metges
Honoraria - BMS; Lilly; Novartis; Sanofi; SynCoreBio
Travel, Accommodations, Expenses - Amgen; Amgen; LEO Pharma; MSD Oncology; MSD Oncology; MSD Oncology
 
Maud Toulmonde
Speakers' Bureau - Blueprint Medicines
Travel, Accommodations, Expenses - PharmaMar
 
Sophie Cousin
No Relationships to Disclose
 
Simon Pernot
No Relationships to Disclose
 
Mariella Spalato
No Relationships to Disclose
 
Thomas Grellety
No Relationships to Disclose
 
Celine Auzanneau
No Relationships to Disclose
 
Barbara Lortal
No Relationships to Disclose
 
Michèle Kind
No Relationships to Disclose
 
François Le Loarer
No Relationships to Disclose
 
Sabrina Sellan-Albert
No Relationships to Disclose
 
Carine A. Bellera
No Relationships to Disclose